Anti-CD19-CAR Retroviral Vector-Transduced Autologous T Cells - CISMeF
Anti-CD19-CAR Retroviral Vector-Transduced Autologous T CellsNCIt concept
Preferred Label : Anti-CD19-CAR Retroviral Vector-Transduced Autologous T Cells;
NCIt definition : A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been genetically
modified to express a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv
(single chain variable fragment) coupled to the costimulatory signaling domain CD28
and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential
immunostimulating and antineoplastic activities. Upon administration, anti-CD19-CAR
retroviral vector-transduced autologous T cells direct the T-lymphocytes to CD19-expressing
tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19
antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage
malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the
TCR/CD3 complex, which regulates both the assembly of complete TCR complexes and their
expression on the cell surface. CD28 is essential for CD4 T-cell proliferation, interleukin-2
production, and T-helper type-2 (Th2) development.;